Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 316


Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.

Tan X, Carretero J, Chen Z, Zhang J, Wang Y, Chen J, Li X, Ye H, Tang C, Cheng X, Hou N, Yang X, Wong KK.

PLoS One. 2013 Nov 15;8(11):e80885. doi: 10.1371/journal.pone.0080885. eCollection 2013.


Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.

Qiu W, Tang SM, Lee S, Turk AT, Sireci AN, Qiu A, Rose C, Xie C, Kitajewski J, Wen HJ, Crawford HC, Sims PA, Hruban RH, Remotti HE, Su GH.

Gastroenterology. 2016 Jan;150(1):218-228.e12. doi: 10.1053/j.gastro.2015.09.013. Epub 2015 Sep 25.


PIK3CA(H1047R) Accelerates and Enhances KRAS(G12D)-Driven Lung Tumorigenesis.

Green S, Trejo CL, McMahon M.

Cancer Res. 2015 Dec 15;75(24):5378-91. doi: 10.1158/0008-5472.CAN-15-1249. Epub 2015 Nov 13.


Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.

Miller A, McLeod L, Alhayyani S, Szczepny A, Watkins DN, Chen W, Enriori P, Ferlin W, Ruwanpura S, Jenkins BJ.

Oncogene. 2017 May 25;36(21):3059-3066. doi: 10.1038/onc.2016.437. Epub 2016 Nov 28.


Mouse model of proximal colon-specific tumorigenesis driven by microsatellite instability-induced Cre-mediated inactivation of Apc and activation of Kras.

Kawaguchi Y, Hinoi T, Saito Y, Adachi T, Miguchi M, Niitsu H, Sasada T, Shimomura M, Egi H, Oka S, Tanaka S, Chayama K, Sentani K, Oue N, Yasui W, Ohdan H.

J Gastroenterol. 2016 May;51(5):447-57. doi: 10.1007/s00535-015-1121-9. Epub 2015 Sep 11.


Opposing role of Notch1 and Notch2 in a Kras(G12D)-driven murine non-small cell lung cancer model.

Baumgart A, Mazur PK, Anton M, Rudelius M, Schwamborn K, Feuchtinger A, Behnke K, Walch A, Braren R, Peschel C, Duyster J, Siveke JT, Dechow T.

Oncogene. 2015 Jan 29;34(5):578-88. doi: 10.1038/onc.2013.592. Epub 2014 Feb 10.


NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.

Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Hussain SP, Harris CC.

Int J Cancer. 2013 Jan 1;132(1):9-18. doi: 10.1002/ijc.27644. Epub 2012 Jun 13.


Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.

Chalabi-Dchar M, Cassant-Sourdy S, Duluc C, Fanjul M, Lulka H, Samain R, Roche C, Breibach F, Delisle MB, Poupot M, Dufresne M, Shimaoka T, Yonehara S, Mathonnet M, Pyronnet S, Bousquet C.

Gastroenterology. 2015 Jun;148(7):1452-65. doi: 10.1053/j.gastro.2015.02.009. Epub 2015 Feb 13.


KLF10 loss in the pancreas provokes activation of SDF-1 and induces distant metastases of pancreatic ductal adenocarcinoma in the KrasG12D p53flox/flox model.

Weng CC, Hawse JR, Subramaniam M, Chang VHS, Yu WCY, Hung WC, Chen LT, Cheng KH.

Oncogene. 2017 Sep 28;36(39):5532-5543. doi: 10.1038/onc.2017.155. Epub 2017 Jun 5.


MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.

Trejo CL, Juan J, Vicent S, Sweet-Cordero A, McMahon M.

Cancer Res. 2012 Jun 15;72(12):3048-59. doi: 10.1158/0008-5472.CAN-11-3649. Epub 2012 Apr 17.


miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.

Kasinski AL, Slack FJ.

Cancer Res. 2012 Nov 1;72(21):5576-87. doi: 10.1158/0008-5472.CAN-12-2001. Epub 2012 Sep 10.


Nitrilase 1 modulates lung tumor progression in vitro and in vivo.

Wang YA, Sun Y, Le Blanc JM, Solomides C, Zhan T, Lu B.

Oncotarget. 2016 Apr 19;7(16):21381-92. doi: 10.18632/oncotarget.7820.


Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).

Wang IC, Ustiyan V, Zhang Y, Cai Y, Kalin TV, Kalinichenko VV.

Oncogene. 2014 Nov 13;33(46):5391-6. doi: 10.1038/onc.2013.475. Epub 2013 Nov 11.


Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis.

Grabner B, Schramek D, Mueller KM, Moll HP, Svinka J, Hoffmann T, Bauer E, Blaas L, Hruschka N, Zboray K, Stiedl P, Nivarthi H, Bogner E, Gruber W, Mohr T, Zwick RH, Kenner L, Poli V, Aberger F, Stoiber D, Egger G, Esterbauer H, Zuber J, Moriggl R, Eferl R, Győrffy B, Penninger JM, Popper H, Casanova E.

Nat Commun. 2015 Mar 3;6:6285. doi: 10.1038/ncomms7285.


Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.

Zhu X, Zhao L, Park JW, Willingham MC, Cheng SY.

Neoplasia. 2014 Sep;16(9):757-69. doi: 10.1016/j.neo.2014.08.003.


Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.

Hill KS, Erdogan E, Khoor A, Walsh MP, Leitges M, Murray NR, Fields AP.

Oncogene. 2014 Apr 17;33(16):2134-44. doi: 10.1038/onc.2013.147. Epub 2013 Apr 22.


Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.

Elsum IA, Yates LL, Pearson HB, Phesse TJ, Long F, O'Donoghue R, Ernst M, Cullinane C, Humbert PO.

Oncogene. 2014 Nov 27;33(48):5523-33. doi: 10.1038/onc.2013.498. Epub 2013 Nov 25.


Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC.

Liu W, Yin Y, Wang J, Shi B, Zhang L, Qian D, Li C, Zhang H, Wang S, Zhu J, Gao L, Zhang Q, Jia B, Hao L, Wang C, Zhang B.

Oncotarget. 2017 Jan 3;8(1):179-190. doi: 10.18632/oncotarget.10162.


Synergistic function of Kras mutation and HBx in initiation and progression of hepatocellular carcinoma in mice.

Ye H, Zhang C, Wang BJ, Tan XH, Zhang WP, Teng Y, Yang X.

Oncogene. 2014 Oct 23;33(43):5133-8. doi: 10.1038/onc.2013.468. Epub 2013 Nov 11.


Ezh2 Acts as a Tumor Suppressor in Kras-driven Lung Adenocarcinoma.

Wang Y, Hou N, Cheng X, Zhang J, Tan X, Zhang C, Tang Y, Teng Y, Yang X.

Int J Biol Sci. 2017 May 16;13(5):652-659. doi: 10.7150/ijbs.19108. eCollection 2017.

Supplemental Content

Support Center